Clinical Trials on Neuroendocrine Tumors in Belgium

Total 576 results

Universitaire Ziekenhuizen KU Leuven

Terminated

18F-MFBG PET Imaging of the Norepinephrine Transporter in Neural Crest and Neuroendocrine Tumors

Neuroendocrine Tumors | Neural Crest Tumor

Belgium
Jules Bordet Institute

Completed

177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs (LUMEN)

Gastroenteropancreatic Neuroendocrine Tumors

Belgium
University Hospital, Antwerp
Erasmus Medical Center; ZonMw: The Netherlands Organisation for Health Research... and other collaborators

Recruiting

Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients (SAUNA)

Gastroenteropancreatic Neuroendocrine Tumor

Netherlands, Belgium
Jules Bordet Institute

Withdrawn

Randomized Phase III of PRRT Versus Interferon (CASTOR)

Gastro-intestinal Neuroendocrine Tumors

Belgium
Advanced Accelerator Applications

Completed

A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours (NETTER-1)

Carcinoid Tumor of the Small Bowel | Neuroendocrine Tumour

United States, United Kingdom, Italy, Belgium, France, Germany, Portugal, Spain
Ipsen

Completed

Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg (CLARINET FORTE)

Midgut Neuroendocrine Tumours | Pancreatic Tumours

Spain, United Kingdom, Denmark, Belgium, Germany, France, Netherlands, Ireland, Italy, Poland
Universitair Ziekenhuis Brussel
Kom Op Tegen Kanker

Recruiting

Phase I/IIa Study of 68GaNOTA-Anti-MMR-VHH2 for PET/CT

Breast Cancer | Melanoma (Skin) | Malignant Solid Tumor

Belgium
GERCOR - Multidisciplinary Oncology Cooperative...
Pfizer; Ipsen

Unknown

A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors (SUNLAND)

Carcinoid Tumors

France, Belgium
Universitaire Ziekenhuizen KU Leuven
University Hospital, Ghent; University Hospital, Antwerp; NETwerk, Belgium

Completed

Al18F-NOTA-octreotide PET Imaging in Neuroendocrine Tumors

Neuroendocrine Tumors

Belgium
Universitaire Ziekenhuizen KU Leuven

Completed

Al18F-NOTA-octreotide PET Imaging of the Somatostatin Receptor in Neuroendocrine Tumors

Neuroendocrine Tumors

Belgium
Camurus AB

Active, not recruiting

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET (SORENTO)

Gastro-enteropancreatic Neuroendocrine Tumor

United States, Belgium, Spain, Netherlands, France, Germany, Israel, Italy, Canada, Australia, Romania, Hungary
Cliniques universitaires Saint-Luc- Université...
Immutep S.A.S.

Terminated

Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides

Melanoma

Belgium
Cliniques universitaires Saint-Luc- Université...
Institut Pasteur

Unknown

Safety and Toxicity Study of Vaccination for Advanced Metastatic Melanoma Patients (THERAVAC)

Melanoma

Belgium
Universitair Ziekenhuis Brussel

Active, not recruiting

Intratumoral Injection of Autologous CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Talimogene Laherparepvec (T-VEC) (myDCTV)

Melanoma

Belgium
University Hospital, Ghent
Jessa Hospital; University Hospital, Antwerp; AZ Sint-Jan AV; AZ Delta; General Hospital... and other collaborators

Terminated

BLood Groups as Biomarker to Optimize Odds of Response to Anti-PD-1 Drugs (BLOOD)

Melanoma | Cancer

Belgium
Bart Neyns

Completed

A Study on the Safety and Immunogenicity of Combined Intradermal and Intravenous Administration of an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Previously Treated Unresectable Stage III or IV Melanoma

Melanoma

Belgium
Ludwig Institute for Cancer Research

Terminated

Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Melanoma

Malignant Melanoma

Belgium
Ludwig Institute for Cancer Research

Terminated

Immunization With the MAGE-3.A1 Peptide Mixed With the Adjuvant CpG 7909 in Patients With Metastatic Melanoma

Malignant Melanoma

Belgium
Cliniques universitaires Saint-Luc- Université...

Terminated

Peptide Vaccination Associated With Tumoral Immunomodulation in Patients With Advanced Metastatic Melanoma

Metastatic Melanoma

Belgium
Cliniques universitaires Saint-Luc- Université...

Terminated

Peptide Vaccinations Plus GM-CT-01 in Melanoma

Metastatic Melanoma

Belgium
Universitair Ziekenhuis Brussel

Completed

Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients

Malignant Melanoma

Belgium
University Hospital, Antwerp

Recruiting

Patient-reported Outcomes in Neuroendocrine Neoplasms: a Prospective Quality of Life and Quality of Care Study Within NETwerk (Quali-NET)

Quality of Life

Belgium
Universitair Ziekenhuis Brussel
University Hospital, Ghent

Recruiting

Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma (COMBI-R2)

Melanoma

Belgium
University Hospital, Ghent
GZA Ziekenhuizen Campus Sint-Augustinus

Completed

A Phase II Trial of Stereotactic Body Radiotherapy With Concurrent Anti-PD1 Treatment in Metastatic Melanoma.

Melanoma

Belgium
Universitair Ziekenhuis Brussel

Recruiting

Biomarkers for the Activity of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Melanoma (ICIT)

Malignant Melanoma

Belgium
European Organisation for Research and Treatment...

Terminated

Vaccine Therapy in Treating Patients With Melanoma of the Eye

Intraocular Melanoma

Belgium, Denmark
University Hospital, Antwerp
Universiteit Antwerpen

Recruiting

A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment (Liquid-NET 2.0)

Neuroendocrine Tumors

Belgium, Cyprus
RayzeBio, Inc.

Active, not recruiting

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy (ACTION-1)

Neuroendocrine Tumors | Carcinoid Tumor | Gastroenteropancreatic Neuroendocrine Tumor | Carcinoid | GEP-NET | Gastroenteropancreatic Neuroendocrine Tumor Disease | Pancreatic NET

Canada, Spain, United States, Netherlands, Belgium, France, Brazil
Asylia Diagnostics BV

Recruiting

Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors

Melanoma | Lung Cancer

Belgium
Universitair Ziekenhuis Brussel

Recruiting

A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma (RegoMel)

Melanoma Stage IV | Melanoma Stage III

Belgium
Universitair Ziekenhuis Brussel

Completed

TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma (TraMel-WT)

Stage IV Melanoma | Stage III Melanoma

Belgium
Federation Francophone de Cancerologie Digestive

Terminated

A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET) (REMINET)

Metastatic/Locally Advanced, Non-resectable, Duodeno-pancreatic Neuroendocrine Tumours

France, Belgium, Germany, United Kingdom
Universiteit Antwerpen
University Hospital, Antwerp; Kom Op Tegen Kanker

Completed

A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment (Liquid-NET)

Neuroendocrine Tumors

Belgium
Bart Neyns
Vrije Universiteit Brussel

Completed

Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma (TriMix-Ipi)

Malignant Melanoma Stage III | Malignant Melanoma Stage IV

Belgium
Pfizer

Completed

A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

Well-differentiated Pancreatic Neuroendocrine Tumor

United States, China, Czechia, India, Japan, South Africa, Slovakia, France, Norway, Romania, Australia, Belgium, Hungary, Italy, Spain
Universitair Ziekenhuis Brussel
RIZIV

Completed

mRNA Electroporated Autologous Dendritic Cells for Stage III/IV Melanoma (DC-MEL)

Malignant Melanoma Stage III | Malignant Melanoma Stage IV

Belgium
4SC AG

Completed

Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1 (MERKLIN2)

Merkel Cell Carcinoma

Spain, Netherlands, Belgium, Germany, France, Italy
Radiotherapie

Completed

Trial of SBRT With Concurrent Ipilimumab in Metastatic Melanoma

Melanoma | Effects of Immunotherapy | Adverse Effect of Radiation Therapy

Belgium
eTheRNA immunotherapies

Terminated

Safety of Intranodal ECI-006 in Melanoma Patients

Melanoma

Belgium, Spain
Universitair Ziekenhuis Brussel

Recruiting

Whole-body DW-MRI and cfDNA Analysis for the Surveillance of Melanoma Patients at High Risk for Recurrence. (DW-MRi)

Melanoma

Belgium
Aprea Therapeutics
Jules Bordet Institute

Terminated

A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma

Melanoma

Belgium
Société Française d'Endoscopie Digestive

Active, not recruiting

Nonfunctioning Small (≤2 cm) Neuroendocrine Pancreatic Incidentaloma

Neuroendocrine Tumors

France, Belgium
GlaxoSmithKline

Completed

Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Patients With Inoperable Metastatic Cutaneous Melanoma

Melanoma

France, Belgium
Novartis Pharmaceuticals

Completed

Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy

Pancreatic Neoplasms | Neuroendocrine Tumor | Neuroendocrine Carcinoma | Islet Cell Carcinoma

United States, Canada, Spain, Argentina, Germany, Belgium, Italy, France, Sweden, Australia, Netherlands
Bristol-Myers Squibb

Active, not recruiting

A Study of Patients Receiving Adjuvant Nivolumab Therapy for Melanoma That Has Been Removed

Melanoma

Belgium, Luxembourg
Novartis Pharmaceuticals

Completed

BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.

Pancreatic Neuroendocrine Tumors (pNET)

France, Spain, Belgium, Germany, Italy, United Kingdom, Austria, Netherlands, United States
Hoffmann-La Roche

Completed

A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma

Metastatic Melanoma

Belgium, Poland
Universitair Ziekenhuis Brussel

Completed

A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases (ipniv)

Stage IV Skin Melanoma | Stage IIIC Skin Melanoma

Belgium
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors (RADIANT-3)

Advanced Neuroendocrine Tumors of Pancreatic Origin

Canada, France, United Kingdom, Taiwan, Belgium, Spain, Netherlands, United States, Italy, Sweden, Switzerland, Thailand, Germany, Greece, Korea, Republic of, Japan, Brazil, Slovakia
University Hospital, Ghent

Completed

Trial of Adaptive 18F-FDG-PET Biological Intensity-modulated Radiotherapy (BG-IMRT) in Patients With Head and Neck Tumor

Head and Neck Tumor

Belgium

Clinical Trials on Neuroendocrine Tumors in Belgium

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Egypt

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations